Stock Ratings / Health Care / ANAB / earnings

PCRX (54) GHRS (58) TYRA (41) AAPG (57) ⌘ Pro Terminal →

AnaptysBio Inc. (ANAB) Next Earnings Date & Expected ±9.8% Move

$48.64 -3.68% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $48.23

AnaptysBio Inc. (ANAB) carries a Roarable Rating of C- (Hold) with 61/100 RQD Confidence. The composite score sits in the neutral Hold band (59–69), meaning current holders don’t need to panic-sell while prospective buyers can wait for a move into the 70+ Buy zone.

📊 Historical Track Record: Scores of 61/100 (C-) historically posted market-perform odds over rolling 90-day windows (+0.5% avg 90D alpha vs SPY) →

ROARABLE C- • HOLD / WATCH Cap $1.44B

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $48.23 (-0.85%)🧬 Disciplined Float (+0.52% YoY Shares)⚙️ Cash Engine: 19/20 (A+) • 8.4% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record: Scores of 61/100 (C-) historically posted market-perform odds over rolling 90-day windows (+0.5% avg 90D alpha vs SPY • 53.9% hit rate — wait for RQD ≥ 70 breakout).

Audit Bucket Track Record →

RQD QUANT TACHOMETERHOLD / WATCH • C-

JEV AI Jury Split (Battleground)

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw C- · Rk C

Each axis scored 0–20

12M PRICE TARGET CONE+1.4% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for ANAB)Realized 20D OHLCV Swing Band: ±9.8%

Deterministic 5-Pillar Attribution (61/100 Composite)

🔍 WHY ANAB SCORES 61/100 (C-) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: Cash Engine Quality+19/20 pts (31% of score)

SEC XBRL FY 2025 (10-K): 8.4% FCF Margin ($19.6M FCF) & 52% Gross Margin

▲ #2 Bullish Driver: SEC 10-K Forensic Risk+13/20 pts (21% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 7/9

▼ #1 Drag / Risk Factor: Whale & Options Positioning7/20 pts (-13 pt drag)

Put hedging (50% put share) caps near-term gamma upside (-13 pts vs max)

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade C-$45.95+1.4% Next Q

Q2 (-2Q)

Grade C$46.61+4.5% Next Q

Q3 (-1Q)

Grade C$48.73-0.2% Next Q

Current

Grade C-$48.64+0.5% Hist 90D α

Trajectory: C- (53) → C- (61)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)GIDEON ASHMERE // FORENSIC SHORT & KILL-SWITCH DOSSIER

⚔️ Adversarial Opposing Case: Why the ANAB Bull Thesis Could Fail

Gideon Ashmere Forensic Desk →

Even with a 61/100 (C-) score, ANAB faces multiple-compression risk if current valuation multiples re-rate toward historical sector medians or if hyperscaler/enterprise customer concentration slows in upcoming 10-Q filings.

⚠️ Forensic Kill-Switch #1

Company executives have done more routine share selling than personal cash buying lately.

⚠️ Forensic Kill-Switch #2

Dilution & Margin Drag: Disciplined Float (+0.52% YoY Shares) — any gross margin slip below 49.5% triggers an automatic RQD downgrade.

⚠️ Forensic Kill-Switch #3

Technical & Forensic Kill-Switch: A daily close below the 50D SMA ($51.76) or 200D SMA ($50.40) invalidates the momentum regime and cuts Target Base ($49.30) toward Bear Floor ($38.45).

🎲 LIVE PREDICTION MARKET ODDS TIED TO $ANAB• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “ANAB Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 61%NO 39%Trade / Inspect Odds →

NEXT EST. WINDOW: Dec 30, 2026 (~58 DAYS)

Historical OHLCV Volatility ±9.8% Swing Band

±$4.77 Expected Swing

MODEL EARNINGS SETUP GAUGE

ANAB Quantitative Pre-Earnings Setup: 61/100

Trailing EPS: $4.25 • YoY Revenue Growth: 157%

Model Bullish Setup (61/100)Model Risk Weight (39/100)

Derived deterministically from RQD cash-flow quality, SEC accrual safety, and institutional flow (not a community poll).

LOG YOUR PERSONAL PRE-EARNINGS STANCE (SAVED LOCALLY IN BROWSER):

Recent SEC Reported Revenue, Net Profit & Diluted EPS Cadence

Period	Filed	Revenue	Net Profit	Free Cash Flow	Gross Margin
FY 2025	2025-12-31	$234.6M	-$13.2M	$19.6M	52%
FY 2024	2024-12-31	$91.3M	-$145.2M	-$135.7M	52%
FY 2023	2023-12-31	$17.2M	-$163.6M	-$120.8M	52%

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher + Options & Swing Structure Desk

Whale Flow & Momentum Playbook: Evaluating ANAB & AI Leaders Without Chasing Tops

✓Institutional whale strikes & implied earnings move audit on ANAB
✓How disciplined traders manage risk using pre-published trigger & invalidation levels
✓Includes nightly RQD rating-change & forensic signal email alerts on tracked leaders

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

ANAB // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -26.00%▼ DESCENDING CHANNEL

2026-10-30O $48.68H $48.97L $47.88C $48.64VOL 293.6K

RES: $68.53SUP: $43.31SMA50: $51.76SMA200: $50.40

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

ANAB Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 ANAB Butterfly Map → + Track ANAB →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

-7.6%/yr Implied 5Y Growth

vs. +157.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on ANAB today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for ANAB. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for ANAB today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (ANAB)

Health Care Rank #185 of 1016 ⚔️ PCRX vs ANAB Full Matrix →

1. Head-to-Head Health Care Peer Comparison (ANAB vs. PCRX, GHRS, TYRA, AAPG)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, AnaptysBio Inc. (ANAB) ranks #185 by composite RQD confidence (61/100, grade C-) and #311 by equity capitalization ($1.44B). Within this direct 5-issuer industry benchmark cohort, ANAB leads on earnings valuation at N/A trailing P/E, while ANAB leads on capital efficiency and profitability with 85.0% ROIC and — gross margin. ANAB currently leads its immediate peer cohort in composite quantitative strength at 61/100 (C-).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
ANAB ACTIVE AnaptysBio Inc.	C-	61/100	—	—	85.0%	-3.68%	$1.44B	Benchmark Subject
PCRX Pacira BioSciences Inc.	D+	54/100	—	79.4%	1.7%	0.00%	$1.45B	/pcrx-vs-anab →
GHRS GH Research PLC	D+	58/100	—	—	—	+3.82%	$1.47B	/ghrs-vs-anab →
TYRA Tyra Biosciences Inc.	D-	41/100	—	—	-35.0%	-1.24%	$1.48B	/tyra-vs-anab →
AAPG Ascentage Pharma Group International American Depository Shares	D+	57/100	—	—	—	-0.70%	$1.39B	/aapg-vs-anab →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001370053

In its most recent audited fiscal period (FY2025, filed 2025-12-31), AnaptysBio Inc. (ANAB) reported GAAP revenue of $234.6M (+157.0% vs. FY2024 revenue of $91.3M , and +1267.4% cumulative change since FY2023) , GAAP net income of -$13.2M, operating cash flow of $19.7M, and free cash flow of $19.6M (+114.5% YoY). On the balance sheet, ANAB closed FY2025 with $364.4M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 7/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$234.6M	-$13.2M	$19.7M	$19.6M	$364.4M	—
FY2024 (FY)	2024-12-31	$91.3M	-$145.2M	-$135.3M	-$135.7M	$483.8M	—
FY2023 (FY)	2023-12-31	$17.2M	-$163.6M	-$120.8M	-$120.8M	—	—

3. ANAB Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is ANAB stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, AnaptysBio Inc. (NASDAQ: ANAB) is rated C- (Hold / HOLD) by Roarable's 5-pillar RQD engine with a composite confidence score of 61/100 at a spot price of $48.64 (-3.68% 1D, market cap $1.44B). Pillar breakdown: Fundamental Cash Engine 19/20, Institutional 13F & Options Flow 7/20, Executive Insider Alignment 13/20, FRED Macro Regime Fit 12/20, and SEC Balance-Sheet Forensics 10/20. Across 1016 tracked Health Care issuers, ANAB ranks #185 in composite RQD confidence.

How does ANAB compare to PCRX and GHRS in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), ANAB carries a Roarable C- (61/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of 85.0%. By comparison, PCRX (Pacira BioSciences Inc.) holds a D+ grade (54/100 RQD, P/E N/A, ROIC 1.7%, cap $1.45B) and GHRS (GH Research PLC) posts a D+ grade (58/100 RQD, P/E N/A, ROIC —, cap $1.47B). Among the 5-stock peer group, ANAB leads on earnings multiple (N/A) while ANAB leads on capital efficiency (85.0% ROIC).

What are the biggest fundamental strengths and SEC risk factors for ANAB?

Per ANAB's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001370053), AnaptysBio Inc. generated $234.6M in revenue (+157.0% YoY), -$13.2M in net income, and $19.6M in free cash flow against $364.4M in total assets and $0 in total debt. Key quantitative strengths: Strong cash generator (steady margins)—profits are backed by real money, not accounting tricks.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is ANAB trading relative to its 50-day, 200-day, and 52-week technical levels?

ANAB last traded at $48.64 (-3.68% on volume of 414,400 shares), positioning the stock -6.03% below its 50-day simple moving average ($51.76) and -3.49% below its 200-day simple moving average ($50.40). Across its 52-week range of $20.18 to $72.36, ANAB sits at the 54.5% percentile with a 14-day RSI of 46.7 (NEUTRAL RANGE) and an implied next-earnings move of ±9.8% ($43.87 to $53.41).

ANAB Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

When is ANAB's next earnings date?

Based on SEC filing cadence, AnaptysBio Inc. (ANAB)'s next quarterly reporting window is estimated around Dec 30, 2026.

How much is ANAB stock expected to move on earnings?

Volatility modeling currently projects a ±9.8% event move for ANAB, spanning a range between $43.87 and $53.41.

Direct Sub-Reports: ANAB RQD Cockpit ANAB 12M Forecast ANAB Earnings & Move ANAB Dividends & DRIP ANAB Insiders & 13F ANAB Whale Options ANAB Profit Sankey ANAB News & Why